| Title |
Brigatinib: First Global Approval
|
|---|---|
| Published in |
Drugs, June 2017
|
| DOI | 10.1007/s40265-017-0776-3 |
| Pubmed ID | |
| Authors |
Anthony Markham |
| Abstract |
Brigatinib (ALUNBRIG™) is a small molecule antineoplastic anaplastic lymphoma kinase (ALK) inhibitor being developed by ARIAD Pharmaceuticals (a wholly-owned subsidiary of Takeda Pharmaceutical Company). In April 2017 brigatinib received accelerated approval in the USA for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. The development of resistance to crizotinib is a therapeutic challenge that has led to the development of second-generation ALK-inhibitors such as brigatinib, which have activity against treatment-resistant ALK mutants. This article summarizes the milestones in the development of brigatinib leading to this first global approval for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 58 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 16% |
| Student > Postgraduate | 6 | 10% |
| Researcher | 5 | 9% |
| Student > Bachelor | 4 | 7% |
| Student > Doctoral Student | 3 | 5% |
| Other | 7 | 12% |
| Unknown | 24 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 12% |
| Chemistry | 7 | 12% |
| Medicine and Dentistry | 6 | 10% |
| Agricultural and Biological Sciences | 4 | 7% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Other | 2 | 3% |
| Unknown | 29 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 July 2017.
All research outputs
#18,560,904
of 22,988,380 outputs
Outputs from Drugs
#3,017
of 3,285 outputs
Outputs of similar age
#242,015
of 317,327 outputs
Outputs of similar age from Drugs
#32
of 36 outputs
Altmetric has tracked 22,988,380 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,285 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one is in the 3rd percentile – i.e., 3% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,327 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.